SignalChem Lifesciences Corporation (SLC) consists of two business divisions, a bioreagent division and a drug discovery division. The bioreagent business was incorporated in 2004 as SignalChem Pharmaceuticals Inc (SCP). Its initial focus was on producing kinase-related products to facilitate biomedical research and drug discovery efforts. The company’s current product catalogue contains more than 2000 products covering >90% kinase targets of the entire kinome and disease-related mutant kinases, epigenetic enzymes, ubiquitinating enzymes and other signaling proteins. The products created by the bioreagent business have given a significant advantage to SLC in its quest to generate novel drug candidates quickly and cost-effectively and this revenue generating business has been the foundation of the company’s drug discovery platform.
SLC’s drug discovery and development division was established in 2012 focusing on developing novel small molecule kinase inhibitors for the treatment of human diseases with unmet medical needs. Our experiences and expertise in the kinase biology and drug discovery and development allow us to deliver novel therapies against new and untapped kinase targets with a greater likelihood of success and better outcomes for patients. This powerful target discovery engine has generated a robust drug candidate pipeline of novel kinase inhibitors for the treatment different type of cancers.
In addition, the bioreagent products can also be used to develop diagnostic kits (Biomarkers) to support discovery and development of drug candidates using a personalized medicine approach. This entails identifying those patients with the related kinase defect and applying a specific targeted therapy against the defective kinase which will improve SLC’s prospects of successful clinical development and improved patient outcome.
SLC’s business strategies in connection to the Company’s unique business structure are to continue generating rapidly growing short-term revenues from the bioreagent and service business while building long term value with significant potential upside from the new drug discovery and development business. The future business of diagnostics in coupling with the company’s kinase expertise will provide a more rational scientific approach to the drug development process thereby providing an effective patient focused therapy while saving time and money.